Systimmune reported that izalontamab brengitecan (iza‑bren) met both progression‑free and overall survival endpoints in a Phase III trial of Chinese patients with advanced triple‑negative breast cancer (TNBC). The readout is a win for licensee Bristol Myers Squibb and validates the antibody‑drug conjugate’s efficacy in a difficult‑to‑treat population. The positive data could trigger regulatory filings in China and support global partnering or filing strategies. Systimmune and BMS will now determine regulatory sequencing and potential label ambitions. The result highlights ongoing momentum for next‑generation ADCs in oncology and may influence competitive positioning and licensing valuations for similar payload‑conjugate programs.